Carlos Daniel Rose

Carlos Daniel Rose is a minority-owned, Hispanic American-owned sole proprietorship based in Chadds Ford, Pennsylvania, registered with the federal government since December 2003. The entity operates as a for-profit organization specializing in providing medical expert services to support the federal government's vaccine injury compensation and litigation processes. Rose has established himself as a specialized medical consultant with deep expertise in evaluating complex vaccine injury claims and providing expert testimony in federal proceedings.

Through federal contract awards, Carlos Daniel Rose has provided medical expert services primarily to the Health Resources and Services Administration (HRSA) in support of the Vaccine Injury Compensation Program (VICP), a no-fault federal program that compensates individuals found to have suffered injuries from certain vaccines. His work encompasses comprehensive medical case reviews, medical record analysis, written evaluations, and expert testimony to support the adjudication of vaccine injury claims. The contract awards have been issued as Blanket Purchase Agreement (BPA) call orders with firm fixed-price structures, ranging in value from $1,125 to $23,250 per individual task order. Many of these awards have been designated as total small business set-asides, reflecting Rose's status as a minority-owned enterprise. In addition to his extensive work with HRSA, Rose has also provided expert witness services to the Department of Justice's Civil Division, demonstrating the breadth of his federal service across multiple agencies. The consistent pattern of contract awards over more than two decades indicates Rose's established reputation and ongoing value as a specialized provider of medical expertise in vaccine injury litigation and compensation matters.

Carlos Daniel Rose currently holds two primary Blanket Purchase Agreement vehicles with HRSA for medical expert services supporting the VICP. The most recent IDV was awarded on July 26, 2024, with a ceiling value of $7,500,000 and a period of performance extending through July 25, 2029, enabling HRSA to efficiently access Rose's specialized medical expertise on an as-needed basis for evaluating complex vaccine injury cases. An earlier BPA vehicle, awarded on April 8, 2021, carried a ceiling value of $7,500,000 and a performance period through April 7, 2026, under which Rose received hundreds of task orders. Both BPA vehicles are single-award agreements with no set-aside designations at the IDV level, though individual task orders issued under these vehicles frequently utilized total small business set-asides. These indefinite delivery vehicles demonstrate HRSA's substantial reliance on Rose's specialized expertise and his critical role in supporting the agency's mandate to administer a no-fault alternative remedy for vaccine injuries while maintaining public confidence in national vaccination programs.